CLS future-proofs its core technology for MRI-guided laser ablation in a new agreement with IGT
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that a new agreement has been signed with its supplier Image Guided Therapy SA (IGT). Under the terms of the agreement, CLS will acquire all rights to IGT's technology for MRI-based temperature measurement and control of laser-based tissue ablation.
The agreement is an important part of the development of the company's technology platform and business strategy. The agreement with IGT means that CLS now owns all rights to its product portfolio and can thus fully secure value creation in the continued work with product development and commercialization.
"IGT currently delivers core technology and expert resources to CLS for the development of the company's products for MRI-guided laser ablation. The new agreement also means that the development collaboration between CLS and IGT is extended, thereby ensuring that the necessary resources and skills continue to be available to support the company's continued product development and commercialization," says Jimmy Johansson, EVP Operations, CLS.
The technology from IGT is currently used in the TRANBERG® Thermal Therapy System with the Thermoguide Workstation, a product that is part of a clinical evaluation of the treatment of localized prostate cancer with focal therapy at Radboud University Medical Center in Nijmegen, the Netherlands. The technology is also used in ClearPoint Prism™ Neuro Laser Therapy System, a product that is in a limited market launch in the US with indications such as brain tumors and drug-resistant epilepsy and which is also included in a clinical study of MRI-guided laser ablation (NeuroLITT) of the tumor disease glioblastoma at Skåne University Hospital in Lund.
Image Guided Therapy SA is a French medical technology company with products for MRI-guided minimally invasive cancer treatment through ablation with focused ultrasound (MRgFUS). Read more here: Image Guided Therapy.
For more information, please contact:
Dan J. Mogren, VD, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40 Email:dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells TRANBERG®|Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancerous tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and are used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund, Sweden, and has subsidiaries in Germany, the USA and Singapore. CLS is listed on Nasdaq First North Growth Market under the ticker CLS B. Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the company's website: www.clinicallaser.se